This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs NN 9277 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 04 Aug 2017 Planned End Date changed from 6 Sep 2017 to 25 Oct 2017.
- 04 Aug 2017 Planned primary completion date changed from 6 Sep 2017 to 25 Oct 2017.
- 16 Nov 2016 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.